Immatics N.V. (IMTX)
Stock Price:
$9.95 USD
-0.42 (-4.05%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
625.94M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-35.20M |
| Shares Out |
62.91M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$9.95 |
| Previous Close |
$10.37 |
| Change ($) |
-0.42 |
| Change (%) |
-4.05% |
| Day's Open |
10.10 |
| Day's Range |
9.74 - 10.32 |
| Day's Volume |
679,850 |
| 52-Week Range |
9.51 - 17.25 |
More Stats
| Market Cap |
625.94M |
| Enterprise Value |
625.30M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
62.91M |
| Float |
646,405 |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
4.16 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
10.86% |
| Payout Ratio |
n/a |
| Shares Short |
13,729 |
| Short Ratio |
0.03 |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
9.21 |
| PS Ratio |
n/a |
| PB Ratio |
137.57 |
| Revenue |
n/a |
| Operating Income |
-36.63M |
| Net Income |
-35.20M |
| Free Cash Flow |
68.00M |
| Net Cash |
638,502 |
| Net Cash / Share |
0.01 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
-190.80% |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$19.85*
(99.48% upside)
Low
14.3
Current: $9.95
High
27.9
Target: 19.85
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | 18.45 | 3.77 |
| Revenue Growth | 389.36% | - |
| Gross Profit | 18.45 | 3.77 |
| Operating Income | -33.01 | -34.41 |
| Net Income | -31.57 | -31.44 |
| Shares Outstanding | 1.16 | 1.16 |
| Earnings Per Share | -27.13 | -27.02 |
| Operating Cash Flow | 68.05 | 7.58 |
| Capital Expenditures | -2.14 | -0.41 |
| Free Cash Flow | 65.91 | 7.17 |
| Cash & Equivalents | 103 | 39.37 |
| Total Debt | 3.23 | - |
| Net Cash / Debt | 100 | 39.37 |
| Assets | 134 | 61.32 |
| Liabilities | 175 | 70.49 |
| Book Value | -41.86 | -10.41 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Immatics N.V. |
| Country |
Germany |
| Employees |
200 |
| CEO |
Harpreet Singh-Jasuja |
Stock Information
| Ticker Symbol |
IMTX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: IMTX |
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors; and IMA204, an anti-tumor therapy that targets the malignant tumor cell. Its TCR Bispecifics product candidates include IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid and hematological malignancies. The company also develops IMA101, a multi-target precision immunotherapy; and IMA301, an off-the-shelf ACT. It has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in Tübingen, Germany.